S. sonnei 1790GAHB

BIOLOGICAL2 trials

Sponsors

GSK Vaccines Institute For Global Health S.r.l.

Conditions

Shigellosis

Phase 1

A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.

CompletedNCT02017899

GSK Vaccines Institute For Global Health S.r.l.Shigellosis

Start: 2014-02-28End: 2015-03-31Updated: 2019-01-23

Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults

CompletedNCT02034500

GSK Vaccines Institute For Global Health S.r.l.Shigellosis

Start: 2014-03-31End: 2015-04-30Updated: 2016-06-21

Related Papers

Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension

Frontiers in Immunology2021-05-0438 citations

A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against Shigella sonnei Administered Intramuscularly to Adults from a Shigellosis-Endemic Country

Frontiers in Immunology2017-12-22107 citations

Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.

2017-07-1595 citations

Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review.

2016-08-0430 citations